Survival and Dialysis Independency in Highly Sensitized Patients After Desensitization With Imlifidase and Tx of Kidneys
← catalyst calendarNCT05714514 · readout in 499 d
Sponsored by Hansa Biopharma AB (industry) · HNSA.ST — their whole pipeline →.
Phase
—
Status
Active, not recruiting
Study type
Observational
Enrollment
64estimated
Sites
14
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2023-04-21 | actual | When the study began enrolling |
| Primary completion | 2027-12-31 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2029-12-31 | estimated | The whole study's end, after follow-up |
| First posted | 2023-02-06 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-11-18 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Kidney Transplantation in Highly Sensitized Patients
Interventions
- Drug: Imlifidase administered in the ConfIdeS study — also filed as IdeS, HMED-IdeS
- Other: Best available treatment administered in the ConfIdeS study
Primary outcome
what the primary-completion date above is the date OFProportion of patients alive and free of dialysis at 3 years
measured 3 years after randomization in the ConfIdeS study
Permalink · HNSA.ST's whole pipeline · Catalyst calendar · Every registered study · What changed